TrialScope Adds Seven Additional Languages to Trial Results Summaries Portal
JERSEY CITY, N.J., July 18, 2017 – TrialScope, a global company in patient-centric clinical trial transparency and compliance solutions, announced that the Trial Results Summaries Portal now supports trial summaries in English and seven additional languages: Chinese, French, German, Japanese, Polish, Russian, and Spanish.
The Trial Results Summaries Portal, launched in February 2017, is designed to improve patient and trial participant access to trial results summaries (also known as lay language summaries) by allowing immediate global web access to trial results summaries.
“Clinical Trial participants and patients want to access to research results, and we are committed to supporting and expanding the transparency efforts of trial sponsors,” said Mark Heinold, TrialScope’s Chief Executive Officer. “We understand the importance of making this information available to trial participants around the world in an accurate and timely manner, and the additional language support is the natural progression of these efforts.”
The Center for Information and Study on Clinical Research Participation (CISCRP) is an independent non-profit organization that specializes in delivering trial results summaries in various formats to patients. Jill McNair, CISCRP’s Senior Director of Patient Engagement, commented, “Communicating trial results summaries in clinical trial participant’s native language is an important step in engaging trial participants, patients and the public while arming a broader audience with important health information.”
The Trial Results Summaries Portal is available at www.trialsummaries.com. Clinical trial sponsors may contact TrialScope to learn more about the benefits, features and pricing of the solution.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
